DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Liu JF, Barry WT, Birrer M. et al.
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Lancet Oncol 2014;
15: 1207-1214
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.